The increasing complexity of clinical trials is driving a necessitate for more rigorous management of investigational drug products, according to guidelines established by the American Society of Health-System Pharmacists (ASHP). Manual processes for controlling patient assignment and drug distribution are proving inadequate, prompting a search for standardized approaches.
The ASHP guidelines, designed for use by clinical research pharmacies, pharmaceutical companies, and research networks, cover the entire lifecycle of investigational drugs – from receipt and storage to dispensing and final disposal. These protocols aim to ensure data credibility and accuracy, as well as protect the rights and confidentiality of trial participants, a standard known as Good Clinical Practice.
A key challenge in clinical trial design is maintaining the integrity of blinding, where participants and investigators are unaware of treatment assignments. Even with blinding protocols, detection of treatment assignment can occur, necessitating pre-specified decision rules and blinded outcome assessments, particularly in open-label trials.
Intervention models, such as cross-over designs, further complicate management. In a two-by-two cross-over assignment, for example, one group of participants receives drug A followed by drug B, while another group receives the drugs in reverse order. This requires meticulous tracking of which participant received which drug and when, to avoid compromising the study’s results.
Accountability for investigational products is paramount. The ASHP guidelines emphasize the need for detailed records of drug receipt, storage conditions, and any discrepancies. This includes procedures for handling expired or unused medication, ensuring proper documentation at every stage.
The FDA highlights the importance of these standards, noting that they provide assurance that reported results are credible and accurate. The agency’s guidance on clinical trial design underscores the need for careful planning and execution to minimize bias and ensure the reliability of findings.
Currently, there is no public indication of forthcoming revisions to the ASHP guidelines, nor any statement from the FDA regarding increased enforcement of existing standards. A meeting of the ASHP investigational drug services advisory group is scheduled for March 15, 2026, to discuss emerging challenges in clinical trial pharmacy practice.
